Photo via Pexels
Aerogels are highly porous, ultralight materials derived from a gel in which the liquid component has been replaced with gas, resulting in a solid with extremely low density and high surface area. When engineered as nanoparticles or microparticles, these aerogels can encapsulate therapeutic agents and be modified for targeted delivery to specific cells or tissues. Research is prominent at ETH Zurich, the University of Cambridge, and the Indian Institute of Science (IISc Bangalore). The technology is currently in the prototype stage, with numerous successful *in vitro* and *in vivo* animal studies. In September 2023, researchers at IISc Bangalore published in *ACS Nano* on silica aerogel nanoparticles designed to release cancer drugs specifically within tumor microenvironments, demonstrating enhanced efficacy and reduced systemic toxicity compared to conventional chemotherapy. This offers a more precise and potent delivery system than standard drug formulations.
Editorial check
How this page is checked
Source trail
chem.wayne.edu
External links are separated from Surfaced commentary.
Reader safety
Context before clicks
Product links and external services are not presented as guarantees.
Monetization
No affiliate flag
Ads and commerce links are kept distinct from editorial text.
Surfaced take
Why It Matters
The pharmaceutical industry faces significant challenges in drug efficacy and patient side effects, with the targeted drug delivery market alone projected to exceed $150 billion by 2030. Aerogel-based systems could revolutionize treatments for cancer, infectious diseases, and chronic conditions by delivering drugs precisely where needed, minimizing harm to healthy tissue and improving patient outcomes. Pharmaceutical companies and biotech startups focusing on novel delivery platforms would gain a significant advantage, potentially disrupting traditional drug formulation methods. Technical barriers include achieving consistent drug loading and release profiles, ensuring biocompatibility and biodegradability, and navigating complex regulatory approval processes for new drug delivery vehicles. Clinical trials are expected within 5-8 years, with pharmaceutical giants and specialized startups globally racing to develop viable products. A profound, second-order consequence could be the re-evaluation of dosages and treatment durations, leading to personalized medicine paradigms that are both more effective and less burdensome for patients.
Development Stage
Related
Scrintal
Scrintal is a visual knowledge canvas and note-taking tool developed by a startup, designed to help users think spatially and connect ideas on an infinite…
Have I Been Pwned (HIBP)
Have I Been Pwned (HIBP) is a free online service created by security expert Troy Hunt, designed to help people check if their email addresses or phone numbers…
Enjoyed this? Get five picks like this every morning.
Free daily newsletter — zero spam, unsubscribe anytime.